Search

Your search keyword '"Denk, Monika"' showing total 18 results

Search Constraints

Start Over You searched for: Author "Denk, Monika" Remove constraint Author: "Denk, Monika"
18 results on '"Denk, Monika"'

Search Results

1. A H3K27M-targeted vaccine in adults with diffuse midline glioma

2. Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency

3. INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas

4. Long-term efficacy of the peptide-based COVID-19 T cell activator CoVac-1 in healthy adults

5. AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas

6. The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma

7. iVAC-XS15-CLL01: personalized multi-peptide vaccination in combination with the TLR1/2 ligand XS15 in CLL patients undergoing BTK-inhibitor-based regimens.

8. A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity

9. FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion

10. Abstract CT258: Interim safety and immunogenicity results of a phase I trial evaluating the multi-peptide COVID-19 vaccine candidate CoVac-1 for induction of SARS-CoV-2 T cell immunity in cancer patients with disease- or treatment-related immunoglobulin deficiency

11. Abstract 3574: A Phase I trial of personalized multi-peptide vaccination in combination with the TLR1/2 ligand XS15 in CLL patients under Bruton-Tyrosin-Kinase-inhibitor based regimes - Preclinical development and study design

12. Abstract 2008: The oncogenic fusion protein DNAJB1-PRKACA can be actively targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma

13. Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency

14. A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity

15. Phase I Trial of a Multi-Peptide COVID-19 Vaccine for the Induction of SARS-CoV-2 T-Cell Immunity

Catalog

Books, media, physical & digital resources